Opus Genetics to Present at RBC Capital Markets Healthcare Conference
Event summary
- Opus Genetics to present at RBC Capital Markets 2026 Global Healthcare Conference on May 19, 2026.
- Presentation scheduled for 11:00 a.m. ET, accessible via live and archived webcast.
- Company focuses on gene therapies for inherited retinal diseases (IRDs) with seven AAV-based programs in pipeline.
- Lead candidates include OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration.
The big picture
Opus Genetics' presentation at the RBC Capital Markets conference comes amid growing interest in gene therapies for inherited retinal diseases. The company's focus on durable, one-time treatments positions it within a competitive but rapidly evolving sector. Success will depend on both clinical outcomes and the ability to secure partnerships or funding to advance its pipeline.
What we're watching
- Clinical Progress
- How the presentation will highlight advancements in OPGx-LCA5 and OPGx-BEST1 programs.
- Investor Sentiment
- Whether the conference will bolster investor confidence in Opus Genetics' pipeline.
- Competitive Positioning
- The pace at which Opus Genetics can differentiate itself in the crowded gene therapy space.